Cot-Effectivene of Monotherapy Treatment of Glaucoma and Ocular Hypertenion With the Lipid Cla of Medication

Purpoe Cot-effectivene evaluation of monotherapy with the newer lipid cla of intraocular preure (IOP)-lowering medication in glaucoma and ocular hypertenion. Deign Retropective pharmacoeconomic analyi. Method Analyi included all publihed tudie meauring IOP reduction from untreated baeline with once-daily bimatoprot (Lumigan), latanoprot (Xalatan), or travoprot (Travatan) monotherapy in patient with elevated IOP. Percentage IOP reduction at the final tudy viit wa calculated uing the early morning IOP meaurement to control for diurnal variation in IOP. Patient-weighted average percentage IOP reduction were computed for each medication. Cot per 2.5-ml bottle wa determined uing PriceAlert 2005 (February). Cot-effectivene wa defined a monthly cot of medication per patient-weighted average 1% reduction in IOP. Reult tudie included 951 bimatoprot, 1598 latanoprot, and 765 travoprot patient. The AWP in February, 2005 for a 2.5-ml bottle wa $62.10 for bimatoprot, $61.29 for latanoprot, and $62.19 for travoprot. Patient-weighted average IOP reduction wa 32.4% for bimatoprot, 29.6% for latanoprot, and 29.0% for travoprot. Calculated cot-effectivene wa $1.92 for bimatoprot, $2.07 for latanoprot, and $2.14 for travoprot. Incremental cot-effectivene ratio (ICER) analyi howed an incremental cot of $0.29 for each additional 1% IOP reduction provided by bimatoprot over latanoprot. The rank order of the cot-effectivene of the drug (bimatoprot > latanoprot > travoprot) wa robut in enitivity analye to cot and efficacy. Concluion On the bai of AWP and patient-weighted average percentage IOP reduction in publihed tudie, bimatoprot had the mot favorable cot-effectivene among the drug compared. Cot-effectivene hould be conidered along with traditional clinical afety and efficacy meaure to make individual and group healthcare deciion.